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The purpose of this study was to evaluate long-term survival benefits of 
bypass surgery and angioplasty versus medical therapy in 9263 patients at 
Duke University Medical Center between 1984 and 1990 with coronary 
artery disease confirmed by cardiac catheterization to involve one, two, or 
three vessels. Clinical data were prospectively entered into an established 
cardiovascular database, and annual follow-up was 97% complete for a 
mean interval of 5.3 years and a maximal interval of 10 years. Outcomes 
were analyzed with the Coronary Artery Surgery Study "method A" to 
define patient groups treated by medicine (n = 2449), angioplasty (n = 
2924), or bypass surgery (n = 3890). Differences among treatment groups 
in baseline characteristics were adjusted by Cox proportional hazard 
models. The anatomic severity of coronary artery stenosis best defined 
survival benefit from bypass surgery and angioplasty versus medical 
treatment. One or both interventional treatments provided better long-term 
survival than did medical treatment for all levels of disease severity. All 
patients with single-vessel disease, except hose with at least 95% proximal 
left anterior descending stenosis, benefited from angioplasty versus bypass. 
All patients with three-vessel disease and those two-vessel patients with 
_>95% proximal left anterior descending stenosis benefited from bypass 
surgery versus angioplasty. All other patients with two-vessel disease and 
those with _>95% proximal left anterior descending stenosis only had 
similar survival with either interventional treatment. The absolute survival 
benefit was greatest for patients with severe three-vessel disease treated 
with bypass surgery. (J Thorac Cardiovasc Surg 1996;111:1013-25) 
C oronary artery bypass grafting (CABG) has been used with increased frequency since its introduc- 
tion into clinical practice more than 25 years ago. 1 
Dramatic increases in the use of percutaneous trans- 
luminal coronary angioplasty (PTCA) during the past 
From the Heart Center and the Departments of Surgery, a 
Medicine, b and Anesthesiology, ° Duke University Medical 
Center, Durham, N.C. 
Supported in part by grants PORT I/AHCPR HS06503 and 
AHCPR HS05635. 
Read at the Seventy-fifth Annual Meeting of The American Asso- 
ciation for Thoracic Surgery, Boston, Mass., April 23-26, 1995. 
Received for publication April 27, 1995; revisions requested June 
13, 1995; revisions received Dec. 7, 1995; accepted for publi- 
cation Dec. 18, 1995. 
Address for reprints: Robert H. Jones, MD, P.O. Box 2986, Duke 
University Medical Center, Durham, NC 27710. 
§By invitation. 
Copyright © 1996 by Mosby-Year Book, Inc. 
0022-5223/96 $5.00 + 0 12/6/71258 
15 years have modified the characteristics of popula- 
tions of patients treated by CABG. 2 The effects of this 
major shift in practice on survival of patients with 
coronary artery disease (CAD) remains unknown. We 
previously reported intermediate-term survival for 
9263 patients with CAD confirmed by coronary an- 
giography at Duke University Medical Center between 
March 1984 and August 1990. 3Detailed description of 
baseline characteristics and prospective follow-up of 
the entire patient cohort provide unique comparative 
data. We now report long-term survival for as long as 
10 years on this patient cohort to establish the relative 
and absolute values of PTCA, CABG, and medical 
treatment and as a general framework of information 
to aid treatment selection for individual patients with 
CAD. 
Methods 
Since 1971, clinical and coronary angiography data have 
been prospectively entered into a database on patients 
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Fig. 1. Schematic diagram summarizes selection of patients for study, mode of assignment to treatment 
groups, and performance of subsequent procedures. 
catheterized atDuke University Medical Center. Between 
March 1984 and August 1990, 11,492 patients were found 
by angiography to have at least 75% stenosis in one or 
more coronary arteries. To select only those patients who 
might be reasonable candidates for either primary CABG 
or PTCA, 2229 patients were excluded because of at least 
50% left main stenosis (n = 691), previous CABG (n = 
527) or PTCA (n = 253), or 3+ to 4+ mitral regurgitation 
(n = 422). The Coronary Artery Surgery Study (CASS) 
"method A" of assignment of patients to treatment sub- 
groups was used. 46 All patients were initially assigned to 
the medical subgroup and remained in this group unless 
CABG or PTCA was performed. For patients undergoing 
revascularization procedures, medical follow-up was cen- 
sored at the time of the procedure and follow-up was 
restarted at a new zero time in the appropriate revascu- 
larization group. Once a patient was assigned to a revas- 
cularization group, all subsequent outcome events were 
assigned to that treatment group regardless of subsequent 
therapeutic crossovers. 
This approach to patient subgrouping resulted in place- 
ment of 9263 patients initially in the medical subgroup, 
2449 of whom remained on medical treatment throughout 
the study (Fig. 1). CABG was performed in 3890 patients 
(42%), and 3080 of these patients (79%) underwent their 
initial procedure within 60 days of cardiac atheterization. 
In the CABG group, 337 patients (9%) underwent subse- 
quent CABG and 257 (7%) patients underwent subse- 
quent PTCA. PTCA was the initial treatment for 2924 
(32%) of the 9263 patients, and 2626 of these patients 
(90%) underwent their initial procedure within 60 days of 
cardiac catheterization. I  the PTCA group, 549 patients 
(19%) underwent subsequent CABG and 1112 patients 
(38%) underwent subsequent PTCA. Subsequent proce- 
dures were more common and occurred earlier in patients 
treated initially with PTCA versus CABG (Fig. 2). Includ- 
ing both initial and secondary procedures, CABG was 
performed in about one half of the 9263 patients and 
PTCA was performed in about one third at some time 
during the 10-year study interval. 
Baseline clinical and cardiac atheterization character- 
istics of the three treatment populations did not change 
substantially from those described previously. ~ Perfor- 
mance of 468 CABG and 136 PTCA procedures removed 
609 patients from the medical group in the interval since 
intermediate-term results were reported. The revascular- 
ization techniques used have been described previously, 
and early mortality rates associated with more recent 
PTCA and CABG procedures were similar to those 
previously described. 
The extent of CAD has long been known to be a 
principal determinant of the survival benefit of revas- 
cularization. This study used a previously described 
anatomic CAD index derived from a group of 6034 
patients with medically treated CAD seen at Duke 
University Medical Center from 1969 to 1984. 7 The 
relative prognostic weight of this CAD severity score 
was determined by the numbers of stenoses of at least 
75% and at least 95%, as well as location and severity of 
stenosis in the left anterior descending (LAD) coronary 
artery. This CAD score was scaled so that zero was the 
risk of cardiac death in patients with no CAD and 100 
was the risk of cardiac death in patients with at least 
95% stenosis of the left main coronary artery. The full 
CAD severity score has 12 levels. In this report, exclu- 
sion of patients with less than 75% stenosis and those 
with left main disease resulted in nine coronary anat- 
omy groups representing a continuum of one-, two-, and 
three-vessel CAD (Fig. 3). 
Patient follow-up data at 6 months and every year on 
the anniversary of initial presentation, obtained by means 
of self-administered questionnaires and telephone con- 
tact, were 97% complete. Deaths were classified by an 
independent mortality committee into cardiovascular nd 
noncardiovascular causes. The primary endpoint for this 
study was cardiovascular death. 
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Fig. 2. Cumulative percentage of patients undergoing a secondary procedure during the 10-year study 
period for patients initially treated with PTCA or CABG. 
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Fig. 3. Coronary anatomy score was derived for 6034 medically treated patients undergoing coronary 
angiography at Duke University Medical Center between 1969 and 1984. The anatomic lassification of 
coronary artery stenosis is related to the corresponding relative prognostic weight. 
Statistical analysis. A Cox proportional hazards re- 
gression model stratified by treatment group was used to 
adjust for baseline differences. An additional model in- 
cluding treatment as a covariate was used to obtain hazard 
ratios. These are presented with 99% confidence limits 
(CL) to compare the relative benefits of each of the three 
possible pairs of the three treatments for each of the 
coronary artery subgroups. Adjusted Kaplan-Meier sur- 
vival curves were constructed for each coronary anatomy 
group and each treatment. The time course of differences 
in survival illustrates the absolute survival differences 
among the three treatments. These data are presented as 
the number of extra patients surviving for each 100 
patients receiving the more beneficial treatment versus 
the treatment with lesser benefit. 
Results 
The mean follow-up interval for the 9263 patients 
after assignment to a treatment group was 5.3 years 
(20th, 50th, and 75th percentiles 3.9, 5.5, and 7.1 
years, respectively). At some time during the 10-year 
study, cardiovascular death occurred in 541 (12%) 
of the 3890 CABG-treated patients, 328 (9%) of the 
2924 of the PTCA-treated patients, and 796 (9% of 
9263, 33% of 2449) of the patients treated medi- 
cally. Separate Cox proportional hazards models in 
the three treatment subgroups identified only nine 
clinical and angiographic haracteristics related to 
cardiac death. The relative importance of seven of 
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Fig. 4. The relative importance of seven most important baseline characteristics for predicting cardiac 
death for patients within the three treatment groups is summarized by the normalized X 2 values of Cox 
models. The Cox model X 2 is influenced both by the relative biologic importance of the variable and its 
prevalence ina population. The hazard ratio of each variable shows the relative increase in mortality versus 
the treatment group average that would be expected for an individual patient if the variable is present at 
the specified level. MED, Medical treatment; CHF, congestive heart failure; MI, myocardial infarction. 
CABG 
Group 
1 42 2Z 
2 191 1~ 
213 t64 
- -  t48 1~ 
- -5  459 332 
~6 320 242 
- -7  683 641 
- -8  ZT0 211 
~9 520 397 
!oo% 
95% 
90% 
85% 
80% 
75% 
70% 
65% 
60% 
itil 
0 2 4 6 0 2 4 6 0 2 4 6 
Years Years Years 
Fig. 5. Adjusted Kaplan-Meier curves for the nine anatomic CAD groups how the time courses of cardiac 
death in the three treatment groups. The numbers of patients in each of the three treatment groups are 
tabulated at 2 and 4 years. 
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Table I. Five-year survival by treatment in each anatomic subgroup 
Coronary 
anatomy Diseased 
group vessels 
CABG PTCA Medicine 
->95% LAD Observed Adjusted Observed Adjusted Observed Adjusted 
1 1 No 0.97 0.92 
2 1 Yes 0.89 0.91 
3 2 No 0.92 0.90 
4 2 Yes 0.81 0.90 
5 1 Yes ->95% Proximal 0.86 0.89 2 Yes ->95% 
6 2 Yes ->95% Proximal 0.87 0.89 3 No Yes 
7 3 Yes Yes 0.85 0.88 
8 3 Yes Proximal 0.81 0.86 
9 3 Yes >--95% Proximal 0.83 0.85 
0.95 0.96 0.94 0.93 
0.93 0.94 0.93 0.91 
0.91 0.92 0.91 0.88 
0.87 0.90 0.91 0.86 
0.85 0.88 0.90 0.83 
0.80 0.85 0.90 0.79 
0.74 0.80 0.89 0.73 
0.83 0.75 0.88 0.67 
0.61 0.68 0.85 0.59 
the nine most dominant variables for predicting 
cardiac death in all three treatment groups is de- 
picted by the relative )(2 (Fig. 4). Corresponding 
hazard ratios relate to the relative increase in risk of 
cardiac death for an individual patient imposed by 
presence of these risk markers. 
The Cox proportional hazards model incorporat- 
ing all significant variables adjusted observed sur- 
vival for differences in clinical and angiographic 
characteristics among the three treatment groups. 
The resulting adjusted Kaplan-Meier 6-year survival 
curves for patients in the three treatment groups 
reflect the expected survival of an average patient in 
each of the nine anatomic subgroups (Fig. 5). Nu- 
meric values for 5-year observed and adjusted sur- 
vival are summarized in Table I. The negative 
influence of anatomic disease severity on survival is 
apparent in all three treatment groups, with mortal- 
ity consistently increasing as a function of increasing 
anatomic subgroup number. In addition, the great- 
est differences among treatment groups are appar- 
ent in those with the most severe disease. 
Patient and practitioner choices of treatment 
were influenced by specific characteristics in individ- 
ual cases (Fig. 6). General knowledge of the benefits 
of specific treatment modalities for differing coro- 
nary anatomies appears to have guided treatment 
selection. Treatment choice for an individual patient 
that would not be usual for the average of the group 
therefore, might suggest unusual clinical features 
that might not be well described in models of data 
for the entire population. Moreover, statistical cer- 
tainty remains influenced by the number of events in 
each treatment subgroup, and statements of treat- 
ment benefit are weakest in treatment subgroups 
containing small numbers of patients. Although 
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Fig. 6. Data reflect actual treatment umbers of patients 
included in this study in each of nine anatomic subgroups 
who received CABG, PTCA, or medical treatment 
(MED). 
statistical models can be used to adjust for differ- 
ences in baseline characteristics within anatomic 
subgroups, the frequency of use of each of the three 
treatments within the nine anatomic subgroups must 
be considered in interpreting comparative data. 
Hazard ratios were calculated from adjusted sur- 
vival in each anatomic subgroup to depict the rela- 
tive benefits of the three possible pairs of treat- 
ments. Hazard ratios comparing CABG and medical 
treatment demonstrate groups 1 through 4 to have 
no significant difference, but the trend in these 
groups favors medicine over CABG for treatment of 
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Fig. 8. Adjusted hazard ratios comparing PTCA and medicine for the nine coronary anatomy groups. VD, 
Number of diseased vessels; 95%, ->95% coronary artery stenosis; Prox, proximal. 
patients with the least severe CAD (Fig. 7). 
CABG improves urvival relative to medical treat- 
ment in subgroups 5 through 9, and the benefit 
increases progressively with increasing CAD se- 
verity. Adjusted hazard ratios comparing PTCA 
and medicine show anatomic groups 1 through 5 
to have a definite survival benefit with PTCA (Fig. 
8). The relative benefit rend among groups is the 
opposite of that of CABG versus medicine. Ad- 
justed hazard ratios comparing relative benefit of 
CABG and PTCA show unequivocal benefit of 
PTCA in groups 1 and 2 (Fig. 9). The mean 
differences in groups 3 and 4 suggest a benefit for 
PTCA, but this difference does not reach statisti- 
cal significance. Group 5 shows equivalent out- 
comes for both interventional procedures. Pa- 
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Fig. 10. Absolute survival advantage ofCABG and PTCA for each coronary anatomy group expressed as 
extra patients expected to survive for each 100 patients receiving the interventional treatment instead of 
medical treatment. 
tients in groups 6 through 9 have greater survival 
when treated with CABG. 
In addition to hazard ratios showing relative risk, 
absolute survival differences expected to result from 
alternate treatment choices are important indicators 
of the magnitude of benefit associated with a treat- 
ment in a given population. Absolute survival ben- 
efit can be expressed as the extra number of patients 
expected to live if the same patient population were 
to receive the better of two treatment options. Data 
depicting the 6-year time course of absolute survival 
advantage of the two interventional treatments were 
expressed as the extra numbers of patients within 
each coronary anatomy group surviving per 100 
patients treated with CABG or PTCA compared 
with survival if these patients had received medical 
treatment (Fig. 10). The absolute survival advantage 
increases as a function of CAD severity in both 
interventional treatment populations and is greatest 
in patients in coronary anatomy group 9 treated with 
CABG. 
Difference in Kaplan-Meier survival curves be- 
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Fig. 11. Absolute survival advantage of CABG for each 
of the nine anatomic subgroups expressed as extra pa- 
tients expected to survive for each 100 patients receiving 
CABG instead of PTCA. 
tween CABG and PTCA treatment groups depict 
the time course over 6 years of the absolute survival 
advantage of CABG versus PTCA. The positive or 
negative difference, xpressed as extra patients per 100 
patients, reflects the average difference in survival 
outcome in each of the nine coronary anatomy groups 
expected if all patients had been treated with CABG 
instead of PTCA (Fig. 11). These data show CABG to 
have a survival disadvantage for patients with the least 
severe CAD and advantage for patients with the most 
severe CAD versus PTCA. Curves describing differ- 
ences in survival for the two interventional therapies 
are not symmetric around zero, and fewer deaths 
result from use of CABG in the less severe coronary 
groups than from use of PTCA in patient subgroups 
with severe CAD. These data predict absolute treat- 
ment-related differences in an average patient in each 
anatomic group, and reasonable clinical judgment 
must be used in flexibly applying these principles to 
selection of treatment in an individual case. Other 
clinical factors known to increase risk, such as severe 
ischemia, would magnify treatment differences ex- 
pected for a specific patient. 
Discussion 
This study provides unique data on a large series 
of consecutive patients with one-, two-, and three- 
vessel CAD, permitting evaluation of clinical factors 
related to survival for patients treated by CABG, 
PTCA, or medical therapy. The anatomic extent of 
CAD was determined to be the dominant variable 
predictive of treatment-related differences. Catego- 
ries of information about coronary anatomy related 
to long-term survival included the number of 75% 
and 95% stenoses and the severity and location of 
LAD coronary involvement. With these anatomic 
descriptors, a nine-level coronary anatomy score was 
found to better define treatment differences than a 
less descriptive classification of one-, two-, or three- 
vessel disease. Survival at all times decreased in all 
treatment groups as a function of increasing CAD 
coronary anatomy score. This relationship was least 
strong in patients treated with CABG, however, and 
was strongest in patients treated medically. 
Hazard ratios comparing each pair of the three 
treatments for each of the nine coronary anatomy 
groups defined clear principles useful in selection of 
treatment for CAD. Either one or both interven- 
tional treatments provided better survival than did 
medical therapy for all coronary anatomy groups. 
The magnitudes of absolute survival difference be- 
tween medical therapy and both interventional ther- 
apies were least for the lowest CAD groups, how- 
ever, and increased progressively through group 9. 
This study is the first to conclusively show survival 
benefit of any interventional therapy over medical 
therapy in patient groups with the least severe forms 
of CAD. 
No randomized trial has yet compared survival 
outcomes of PTCA and medical treatment because 
of the large sample size needed to show benefit in 
the population with one- or two-vessel CAD, which 
typically has a low cardiac death rate. The ACME 
trial is the only randomized trial that has compared 
PTCA with medical therapy. 8 This trial, conducted 
on 212 patients with single-vessel disease, was de- 
signed to evaluate the effectiveness of PTCA in 
relieving myocardial ischemia. In this study, PTCA 
decreased the incidence of symptomatic ischemia 
and was associated with more normal results of 
treadmill examinations. 
Yusuf and colleagues 9 performed a metaanalysis 
on the outcomes of 2649 patients randomly assigned 
to receive CABG or medical management for CAD 
in seven individual trials conducted between 1972 
and 1984. These data documented the survival ben- 
efit of CABG to be greatest for patients with 
anatomically severe CAD, indexed by number of 
diseased vessels and the presence of LAD disease. 
Although there were 1130 patients with one-vessel 
or two-vessel disease, the risk was low and only 113 
deaths overall had occurred at 5 years. A nonsignif- 
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icant trend toward lower mortality with CABG was 
observed (one-vessel odds ratio 0.54 [95% CL 0.22 
to 1.33]; two-vessel odds ratio 0.84 [95% CL 0.54 to 
1.32]). Mortality at 5 years was also significantly 
lower with CABG among 1341 patients with three- 
vessel disease (odds ratio 0.58 [95% CL 0.42 - 
0.80],p < 0.001). This odds ratio was similar to that 
determined for the 2771 patients in this study with 
three-vessel disease (0.44 [95% CL 0.27 to 0.74]). 
Comparison of the hazard ratios of patients 
treated with PTCA and CABG in this study show a 
clear relationship to the anatomic extent of CAD 
that favors PTCA in patients with the least severe 
disease and CABG in patients with the most severe 
disease. All patients with single-vessel disease, ex- 
cept those with at least 95% proximal LAD stenosis, 
benefited from PTCA versus CABG. All patients 
with three-vessel disease and patients with two- 
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vessel disease and at least 95% proximal LAD 
stenosis benefited from CABG versus PTCA. All 
other patients with two-vessel disease and those with 
at least 95% proximal LAD stenosis only had similar 
survival with either interventional treatment. Abso- 
lute survival benefits increased with increasing ana- 
tomic severity in both the PTCA and CABG groups, 
but the magnitude of this increase was greatest with 
CABG. Additionally, PTCA is associated with a 
greater need for secondary revascularization proce- 
dures than is CABG. 
Results have been reported for four randomized 
trials, three of which have been published, compar- 
ing PTCA and CABG for treatment of multivessel 
CAD. 1°-12 The individual results of these trials and 
their data combined by metaanalysis fail to show a 
difference in total mortality between CABG and 
PTCA treatment for 2794 patients with two- or 
three-vessel CAD. When survival is compared for a 
single group including all 3648 patients with two- or 
three-vessel CAD undergoing CABG or PTCA in 
this current study, the resulting odds ratio does not 
show significant benefit for CABG and does not 
differ significantly from that of the combined ran- 
domized clinical trial data (Fig. 12). Only when 
patients with two- and three-vessel CAD in this 
current study are more appropriately categorized by 
coronary anatomy score can differences between 
PTCA and CABG be appreciated. These previously 
reported randomized trials did not use a coronary 
disease index similar to that of the Duke Cardiovas- 
cular Database. In the future, it will be useful to 
compare results from randomized and observational 
studies to cross-validate r sults of both methodolo- 
gies. Results of this study suggest, however, that the 
"no survival difference between PTCA and CABG 
for multivessel CAD treatment" conclusion of these 
trials may change to "benefit from PTCA for some 
patients with two-vessel CAD and benefit from 
CABG for most patients with three-vessel CAD." 
This change in conclusion is likely to require that 
larger study populations with more detailed escrip- 
tions of coronary anatomy be used in analysis of trial 
results. 
To the degree that the results of this study from 
a single institution can be generalized to other 
care environments, an expected frequency of use 
of treatments for CAD can be estimated from the 
cumulative percentage ofpatients as a function of 
CAD severity documented by appropriately indi- 
cated coronary angiography (Fig. 13). The cohort 
of patients considered for intervention must be 
increased to include patients with left main dis- 
ease who are known to benefit from coronary 
bypass. PTCA definitely offers survival benefit o 
the 35% of the patient population in coronary 
anatomy groups 1 and 2. Although PTCA does not 
offer statistically significant survival benefit o the 
15% of patients in groups 3 and 4, the trend in 
survival comparison favors this modality, which 
also is less invasive than CABG and therefore is 
the most likely choice of interventional treatment 
for patients in these groups. The 10% of patients 
in group 5 show no clear benefit for either treat- 
ment. The remaining 40% of catheterized patients 
with three-vessel and left main disease benefit 
significantly from CABG. 
Data presented in this report provide a concep- 
tual framework to aid selection of treatment for an 
individual patient with CAD. Many of the treatment 
differences found to be statistically significant are of 
borderline clinical significance because of modest 
differences demonstrated in absolute survival rates. 
Additionally, this reports focuses only on cardiac 
survival as an outcome, and many other outcomes 
validly influence choice of therapy by patients and 
practitioners. Principles defined by this work are 
compatible with two clinical practice guidelines de- 
veloped by national groups from scientific evidence 
and expert opinion. 13' 14 This entire base of knowl- 
edge must be flexibly applied according to good 
clinical judgment to provide the highest quality of 
care for each individual patient. 
This study has several imitations. Treatment 
was not randomly assigned, and choice of treat- 
ment was influenced by factors considered likely 
to optimize outcome. The validity of comparisons 
of effectiveness of treatments herefore depends 
on accurate statistical adjustment for differences 
in baseline characteristics. Although accuracy of 
this adjustment cannot be directly assessed, com- 
parison of outcome data from the Duke Cardio- 
vascular Database adjusted by these methodolo- 
gies has in the past been shown to be comparable 
to outcome data assessing treatment differences 
for similar patients tudied in randomized clinical 
trials, is The similarity of outcomes by two com- 
parisons with randomized trial data of results of 
this study further support he reasonableness of 
using statistical adjustment to correct observed 
results for baseline patient differences among 
treatment groups. Substantial differences among 
the three treatment groups were observed in 
important baseline characteristics, however, such 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 5 
Jones et al. 1023  
as anatomic extent of CAD and incidence of acute 
myocardial infarction. Available randomized trial 
data are inadequate to test the validity of our 
statistical adjustment across this wide range of 
clinical variables. 
Another limitation of the study is definition of 
treatment groups. The technique of identifying 
time zero of the interventional groups by the time 
of initial therapy places all deaths during the 
waiting period for interventional therapy in the 
medical cohort. This influence is balanced to some 
extent by the fact that any subsequent cardiac 
deaths among patients whose conditions deterio- 
rate with medical treatment and who underwent 
myocardial revascularization are attributed to the 
interventional procedure, even though deteriora- 
tion during medical treatment might have contrib- 
uted to the ultimate outcome. Because few deaths 
attributed to the medical cohort occurred early 
after cardiac catheterization, most such deaths 
apparently followed the decision to pursue medi- 
cal therapy as the definitive treatment. The study 
design used, which permits the strategy of initially 
pursuing medical therapy with the option to ob- 
tain a subsequent interventional procedure, mim- 
ics commonly used clinical care strategies. Use of 
an initial period of medical treatment o evaluate 
the response of an individual patient before con- 
sidering interventional therapy was common dur- 
ing this study, and continued use of this strategy is 
supported by study results, especially for patients 
with less severe CAD. 
A concern inherent in all clinical trials is that 
improvements in therapy occurring during the inter- 
val needed for follow-up may partially invalidate 
evaluation of the therapy before these improve- 
ments. Although CABG has been the most com- 
monly performed cardiac operation for more than 
two decades, refinements of anesthetic and opera~ 
tive techniques and postoperative care continue to 
improve outcomes of this procedure. Use of stents is 
becoming common in PTCA and may enhance the 
effectiveness of this therapy. In addition, medical 
therapy now often involves application of aggressive 
behavior modification to decrease or prevent the 
risk of untoward events from documented CAD. 
Prospective compilation of clinical information on a 
consecutive cohort of well-defined patient popula- 
tions with CAD and follow-up of outcomes of 
treatment provide the best approach to evaluate the 
value of these changes for patients with CAD. 
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Discuss ion  
Dr. John W. Kirklin (Birmingham, Ala.). Dr. Jones, my 
colleague Gene Blackstone and I congratulate you on an 
exquisite, masterly, and epochal presentation. We are not 
casual observers of your work, but rather are intense 
students of it. Our own work during this period has 
emphasized the time-related hazard function rather than 
the hazard ratio and patient-specific predictions of out- 
comes after alternative forms of therapy rather than 
average values. These are all details, however, that when 
well understood lead to similar conclusions. These some- 
what parallel courses have given us a high respect for your 
work. 
You and your colleagues have today undertaken a 
Herculean task, the task of presenting tous in understand- 
able form highly relevant information generated by at 
least 10 years of clinical and statistical work by one of the 
most talented and experienced groups in the world, 
headed by you and Dr. Frank Harrell. 
Dr. Jones has presented this information in a natural 
language, English. In contrast, the work has been done, 
and could only have been done, in the language of 
mathematics. He has thus been required to present to us a 
translation from mathematics to the English language, and 
in such translations at least a little is always lost. 
The only contribution we can make to Dr. Jones' 
masterly presentation comes from the friendly and re- 
spectful competition they have allowed us to develop with 
them, which has led to our ability to translate back and 
forth, so to speak. As Dr. Jones has told you, this work has 
been done in the domains of Cox hazard ratios and of 
average values (Discussion Fig. 1). As described in detail 
in the paper itself, which Dr. Jones was kind enough to 
send us a few weeks ago, these categories are not 
strictly those of the extent of the CAD. Rather, the 
number, severity, and location of the stenoses contrib- 
ute to the categorization aswell, as you probably noted 
on the slides. The dot between one-vessel and two- 
vessel disease is thus neither of these categories, but is 
in fact an intermediate one between the two. There are 
two categories between two-vessel and three-vessel 
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Discussion Fig. 2. Hazard ratio versus relative "risk." 
l-V, one-vessel disease; 2-E two-vessel disease; 3-V, 
three-vessel disease. 
CAD, and so forth. You may recall from the slides that 
a 95% left main stenosis was associated with a relative 
risk of 100. "Risk" is in quotes because it is in a way 
shorthand for a more complicated expression. Dr. Jones 
has already emphasized, very appropriately in our 
judgment, hat the more severe the CAD category, the 
greater the so-called risk imposed by the disease. For 
this concept, he has used "relative prognostic weight." 
An enormous amount of work lies behind this relatively 
simple depiction. 
This (Discussion Fig. 2) is conceptually identical to Dr. 
Jones' Fig. 9, and I show this simplified version only to 
underline the importance of his message. Dr. Jones and 
colleagues work and think in terms of the hazard ratio. 
Ratios less than 1.0 indicate increasing effectiveness or
efficiency of CABG over PTCA and ratios greater than 1.0 
depict lessened efficacy. In other words, the hazard ratio is 
the inverse of efficacy. This again states the point that Dr. 
Jones and colleagues have discovered, namely that the 
effectiveness of CABG over PTCA gets greater, as shown 
by the decreasing hazard ratio, as the severity of CAD 
increases. 
Dr. Smith. I believe that your use of our data points out 
one of the advantages that we need to enjoy more, which 
is sharing of the individual patient individual data so that 
they can be compared by multiple methods. It is difficult to 
compare our data with other data, and as you see, we have 
presented CAD as more of a continuous variable than the 
usual classification as one-, two-, and three-vessel disease. 
Access to the raw data and sharing between institutions 
are important features to advance our understanding of 
coronary disease. 
Although these data support he concept that revascular- 
ization improves relative survival for all patients with signif- 
icant-that is, greater than 75% stenosis--coronary disease, 
the absolute magnitude of the survival benefit is greatest for 
patients with three-vessel disease or two-vessel disease with 
95% proximal LAD stenosis. Other attributes known to 
affect surgical risk and enhance surgical outcome must be 
considered when evaluating individual patients within this 
framework. The ultimate indications for PTCA and CABG 
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will also depend on symptomatic relief, freedom from rein- 
tervention, cost, and economic benefit. Reduction of CABG 
cost, effective rehabilitation after CABG, and reduction in 
mortality and morbid complications continue to be major 
goals for thoracic surgeons. 
Appendix 1" 
Survival equation: 
S, = S o (t)exp(x) 
The probabil ity of being alive at any t ime So0 is equal to 
the underlying populat ion survival curve S O at t ime t raised 
to the e x power, where 
e = base of the natural  ogarithm 
x = azy ~ + ay2 + "'" + al& 
"The appendix has been provided at the request of the Editor. 
This appendix should not be used by other institutions that 
might define these variables differently or whose treatment 
approaches might differ from those of the authors and 
influence the relative weight of these variables. The interested 
reader may obtain a copy of the variance-covariance matrix 
from the authors. 
where Yl, Y2, " " ", and Yk are the characteristics and al, 
a2, • " •, and a~ are the corresponding Cox proport ional  
hazard regression coefficients. 
The predictive characteristics are listed in Appendix 
Table 1 with their coefficients. 
Appendix Table 1. Cox propor t iona l  hazards  mode l  
SE 
Coefficient (coefficient) 
CAD index 0.02896 0.00280 
Age 0.04022 0.00270 
EF (truncated at 0.60) -0.04708 0.00224 
Mitral insufficiency 0.13173 0.03633 
Gender 0.09712 0.05594 
Vascular disease index 0.32631 0.03599 
CHF (yes/no) 0.59149 0.06079 
Comorbidity 0.51628 0.07021 
MI/unstable angina index -0.14405 0.01529 
Chest pain (yes/no) -0.14113 0.06652 
PTCA/CAD index 0.00213 0.00544 
CABG/CAD index -0.02904 0.00465 
Centering constant 0.6068266 
CAD, Coronary artery disease; EF, ejection fraction; CHF, congestive 
heart failure; M[. myocardial infarction; PTCA, percutaneous transluminaI 
corona~ angioplasty; CABG, coronary artery bypass grafting; SE, standard 
error. 
